Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center"><em>- SB206 demonstrates continued favorable safety profile consistent with previous studies and meets Company's expectations -</em><br /></p> <p align="center"><em>- Pre-NDA meeting with the FDA, as well as conduct of customary stability testing, targeted for 1H 2022 -</em></p> <p align="center"><em>- Potential NDA submission on track, targeting...